Publications by authors named "Brett Jepson"

Claim this Profile
I
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.
Sue Ann Costa Clemens, Brett Jepson, Qasim E Bhorat, Abdullahi Ahmad, Tauseefullah Akhund

Lancet Microbe· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Maheshi N Ramasamy, Elizabeth J Kelly, Seth Seegobin, Paul I Dargan, Ruth Payne, Brett Jepson

Lancet Microbe· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world effectiveness of benralizumab in US subspecialist-treated adults with severe asthma: Findings from CHRONICLE.
Reynold A Panettieri, Njira Lugogo, Wendy C Moore, Bradley E Chipps, Brett Jepson

Respir Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated.
Jill Maaske, Stephanie Sproule, Ann R Falsey, Magdalena E Sobieszczyk, Anne F Luetkemeyer, Brett Jepson

Front Immunol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic Bioavailability of Sublingual Atropine Ophthalmic Solution: a Phase I Study in Healthy Volunteers with Implications for Use as a Contingency Medical Countermeasure.
Michael D Schwartz, Robert Raulli, Judith W Laney, William Coley, Robert Walker, Brett Jepson

J Med Toxicol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination.
Taylor S Cohen, Elizabeth J Kelly, Sven Nylander, Himanshu Bansal, Brett M Jepson

Sci Rep· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection.
Shuo Feng, Daniel J Phillips, Thomas White, Homesh Sayal, Parvinder K Aley, Brett Jepson

Nat Med· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial.
Teruaki Nakatsuji, Tissa R Hata, Yun Tong, Joyce Y Cheng, Faiza Shafiq, Brett Jepson

Nat Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults.
Christine M Oshansky, James King, Di Lu, James Zhou, Corrina Pavetto, Brett Jepson

NPJ Vaccines· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lower influenza-specific cell-mediated immune responses in individuals with atopic dermatitis compared with healthy controls.
Emilie Jalbert, Stephanie Lussier, Michael J Johnson, Brett Jepson, Agustin Calatroni

Hum Vaccin Immunother· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of BioThrax® and AV7909 anthrax vaccines in adults 66 years of age or older.
Daniel N Wolfe, Eric M Espeland, Yonghong Gao, Di Lu, Gretta Blatner, Brett M Jepson

Vaccine· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptome networks identify mechanisms of viral and nonviral asthma exacerbations in children.
Matthew C Altman, Michelle A Gill, Elizabeth Whalen, Denise C Babineau, Baomei Shao, Brett Jepson

Nat Immunol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with Atopic Dermatitis Colonized with Staphylococcus aureus Have a Distinct Phenotype and Endotype.
Eric L Simpson, Miguel Villarreal, Brett Jepson, Nick Rafaels, Gloria David

J Invest Dermatol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics.
Gordon C Weir, Mario R Ehlers, Kristina M Harris, Sai Kanaparthi, Alice Long, Brett Jepson

Pediatr Diabetes· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A clinical trial of intradermal and intramuscular seasonal influenza vaccination in patients with atopic dermatitis.
Donald Y M Leung, Brett Jepson, Lisa A Beck, Jon M Hanifin, Lynda C Schneider

J Allergy Clin Immunol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Duvuru Geetha, Ulrich Specks, John H Stone, Peter A Merkel, Philip Seo, Brett Jepson

J Am Soc Nephrol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
Ulrich Specks, Peter A Merkel, Philip Seo, Robert Spiera, Carol A Langford, Brett Jepson

N Engl J Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis